These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1111463)

  • 1. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of Kahler's disease].
    Foa J; Carcassonne Y
    Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrosoureas in multiple myeloma.
    Salmon SE
    Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results with the use of the M-2 protocol in plasmacytoma].
    Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
    Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 14. Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
    Strobel ES; Bauchmüller K; Schmitt-Gräff A; Engelhardt M
    Ann Hematol; 2005 Nov; 84(12):830-2. PubMed ID: 16132908
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 17. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
    Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.